Original Research

Psychiatric uses of topiramate: What is the current evidence?

Pierre M Joubert
South African Journal of Psychiatry | Vol 14, No 2 | a157 | DOI: https://doi.org/10.4102/sajpsychiatry.v14i2.157 | © 2008 Pierre M Joubert | This work is licensed under CC Attribution 4.0
Submitted: 15 September 2008 | Published: 01 June 2008

About the author(s)

Pierre M Joubert, Department of Psychiatry, School of Medicine, Faculty of Health Sciences, University of Pretoria and Weskoppies Hospital, Pretoria

Full Text:

PDF (128KB)


Topiramate enhances gamma-amino-butyric acid effects, has anti- glutaminergic effects, and is a state-dependent sodium channel blocker. 1 It is registered as an adjunctive treatment for epilepsy but is not registered for psychiatric indications. Nevertheless, it may be useful beyond its initial indication, considering the promising literature on which I report below. However, much more research evidence is needed to establish sufficient scientific justification for prescribing it routinely for psychiatric purposes.


No related keywords in the metadata.


Total abstract views: 2898
Total article views: 1894

Crossref Citations

No related citations found.